Protocol Ledger

NCT03960580 · Phase III · COMPLETED

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

Interventional Phase III clinical trial protocol NCT03960580 sponsored by Optinose US in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-06 Enrollment: 223 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03960580
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)223 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03960580
Protocol FieldVerified Registry Value
NCT IdentifierNCT03960580
Consolidated Lead SponsorOptinose US
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment223 participants (ACTUAL)
Registered Start Date2019-06-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03960580
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI